Corbus Pharmaceuticals (CRBP) Competitors

$12.00 -0.15 (-1.20%)

As of 10:46 AM Eastern

CRBP vs. BIOA, CTMX, SLDB, AVTE, and ARVN

Should you buy Corbus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corbus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corbus Pharmaceuticals include BioAge Labs (BIOA), CytomX Therapeutics (CTMX), Solid Biosciences (SLDB), Aerovate Therapeutics (AVTE), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.

How does Corbus Pharmaceuticals compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Corbus Pharmaceuticals has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	78.88	-$80.61M	-$2.40	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

Corbus Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Corbus Pharmaceuticals	N/A	-72.32%	-62.96%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioAge Labs currently has a consensus price target of $45.00, indicating a potential upside of 145.83%. Corbus Pharmaceuticals has a consensus price target of $42.33, indicating a potential upside of 246.85%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.73

BioAge Labs has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, meaning that its share price is 168% more volatile than the broader market.

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than BioAge Labs. MarketBeat recorded 22 mentions for Corbus Pharmaceuticals and 10 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.79 beat Corbus Pharmaceuticals' score of 0.73 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corbus Pharmaceuticals beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

CytomX Therapeutics currently has a consensus price target of $12.78, indicating a potential upside of 241.20%. Corbus Pharmaceuticals has a consensus price target of $42.33, indicating a potential upside of 246.85%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 22 articles in the media. CytomX Therapeutics' average media sentiment score of 0.75 beat Corbus Pharmaceuticals' score of 0.73 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corbus Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Corbus Pharmaceuticals	N/A	-72.32%	-62.96%

CytomX Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	17.93	-$17.37M	-$0.41	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

CytomX Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, suggesting that its share price is 168% more volatile than the broader market.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats Corbus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Corbus Pharmaceuticals' return on equity of -72.32% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-86.46%	-69.64%
Corbus Pharmaceuticals	N/A	-72.32%	-62.96%

Solid Biosciences is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Corbus Pharmaceuticals had 15 more articles in the media than Solid Biosciences. MarketBeat recorded 22 mentions for Corbus Pharmaceuticals and 7 mentions for Solid Biosciences. Corbus Pharmaceuticals' average media sentiment score of 0.73 beat Solid Biosciences' score of -0.31 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences currently has a consensus price target of $16.36, suggesting a potential upside of 115.54%. Corbus Pharmaceuticals has a consensus price target of $42.33, suggesting a potential upside of 246.85%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.73

Solid Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, meaning that its stock price is 168% more volatile than the broader market.

Summary

Corbus Pharmaceuticals beats Solid Biosciences on 9 of the 13 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Corbus Pharmaceuticals' return on equity of -72.32% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Corbus Pharmaceuticals	N/A	-72.32%	-62.96%

Corbus Pharmaceuticals has a consensus price target of $42.33, suggesting a potential upside of 246.85%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.73

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, suggesting that its stock price is 168% more volatile than the broader market.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

In the previous week, Corbus Pharmaceuticals had 22 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 22 mentions for Corbus Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Corbus Pharmaceuticals' average media sentiment score of 0.73 beat Aerovate Therapeutics' score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Corbus Pharmaceuticals	Positive

Summary

Corbus Pharmaceuticals beats Aerovate Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Arvinas?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Corbus Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-72.32%	-62.96%
Arvinas	-247.54%	-44.38%	-28.38%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Corbus Pharmaceuticals has a beta of 2.68, suggesting that its share price is 168% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Corbus Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Arvinas	$262.60M	2.37	-$80.80M	-$1.28	N/A

In the previous week, Arvinas had 4 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 26 mentions for Arvinas and 22 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.73 beat Arvinas' score of 0.49 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals currently has a consensus price target of $42.33, suggesting a potential upside of 246.85%. Arvinas has a consensus price target of $15.14, suggesting a potential upside of 56.69%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.73
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Corbus Pharmaceuticals and Arvinas tied by winning 8 of the 16 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$216.08M	$3.04B	$6.30B	$12.38B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-2.09	18.68	20.95	25.53
Price / Sales	N/A	281.59	549.40	73.70
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	1.45	4.32	9.81	6.62
Net Income	-$78.54M	$72.19M	$3.55B	$333.63M
7 Day Performance	12.28%	-1.53%	-1.04%	-0.33%
1 Month Performance	21.81%	-0.61%	0.67%	3.48%
1 Year Performance	73.37%	45.23%	40.04%	35.08%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	2.7069 of 5 stars	$12.00 -1.2%	$42.33 +252.7%	+67.4%	$210.44M	N/A	N/A	40	Trending News Earnings Report Analyst Forecast Analyst Revision
BIOA BioAge Labs	3.1121 of 5 stars	$16.63 -0.9%	$46.25 +178.1%	N/A	$736.09M	$9.00M	N/A	N/A	Earnings Report Analyst Forecast
CTMX CytomX Therapeutics	2.7928 of 5 stars	$4.17 -0.4%	$13.44 +222.8%	+51.6%	$712.40M	$76.20M	N/A	170	Trending News Earnings Report Analyst Forecast Analyst Revision
SLDB Solid Biosciences	2.9113 of 5 stars	$7.21 +1.1%	$16.09 +123.3%	+164.5%	$710.44M	N/A	N/A	100	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
AVTE Aerovate Therapeutics	N/A	$24.23 -0.7%	N/A	+194.1%	$702.31M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. BIOA, CTMX, SLDB, AVTE, and ARVN

How does Corbus Pharmaceuticals compare to BioAge Labs?

Summary

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Solid Biosciences?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. BIOA, CTMX, SLDB, AVTE, and ARVN

How does Corbus Pharmaceuticals compare to BioAge Labs?

Which has better valuation and earnings, BIOA or CRBP?

Is BIOA or CRBP more profitable?

Do institutionals & insiders have more ownership in BIOA or CRBP?

Do analysts rate BIOA or CRBP?

Which has more volatility & risk, BIOA or CRBP?

Does the media favor BIOA or CRBP?

Summary

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

Do analysts recommend CTMX or CRBP?

Does the media prefer CTMX or CRBP?

Is CTMX or CRBP more profitable?

Which has better valuation and earnings, CTMX or CRBP?

Which has more risk & volatility, CTMX or CRBP?

Do insiders and institutionals have more ownership in CTMX or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Solid Biosciences?

Is SLDB or CRBP more profitable?

Which has higher valuation & earnings, SLDB or CRBP?

Do insiders and institutionals hold more shares of SLDB or CRBP?

Does the media favor SLDB or CRBP?

Do analysts prefer SLDB or CRBP?

Which has more volatility & risk, SLDB or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Is AVTE or CRBP more profitable?

Do analysts rate AVTE or CRBP?

Do insiders & institutionals hold more shares of AVTE or CRBP?

Which has more volatility and risk, AVTE or CRBP?

Which has higher valuation and earnings, AVTE or CRBP?

Does the media refer more to AVTE or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Arvinas?

Is CRBP or ARVN more profitable?

Do insiders & institutionals believe in CRBP or ARVN?

Which has more volatility & risk, CRBP or ARVN?

Which has better earnings & valuation, CRBP or ARVN?

Does the media prefer CRBP or ARVN?

Do analysts recommend CRBP or ARVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools